Kedrab
Payments companies reported to CMS as associated with Kedrab. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Kedrab, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Kedrab
These are the largest totals companies reported as associated with Kedrab. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Gerami Seitzman | San Francisco, CA | Ophthalmology | $50,542.41 |
| Angela Zhu | Miami, FL | Ophthalmology | $26,060.54 |
| Joseph Parker | Washington, DC | Sleep Medicine (Internal Medicine) | $25,050.00 |
| Tammuella Chrisentery-Singleton | New Orleans, LA | Pediatric Hematology-Oncology | $14,170.41 |
| Amol Sura | San Francisco, CA | Ophthalmology | $8,900.03 |
| Patricia Klassa | West Bloomfield, MI | Clinical Nurse Specialist | $8,319.66 |
| Rami Aboumourad | Miami, FL | Optometrist | $6,435.14 |
| Arash Mahajerin | Orange, CA | Pediatric Hematology-Oncology | $6,000.00 |
| Bennie Jeng | Philadelphia, PA | Ophthalmology | $4,800.00 |
| Bob Geng | San Diego, CA | Allergy & Immunology | $4,772.52 |
Prescribed Kedrab?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.